BlackRock’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.1M | Sell |
4,521,343
-392,285
| -8% | -$1.05M | ﹤0.01% | 3257 |
|
|
2025
Q1 | $6.93M | Sell |
4,913,628
-98,229
| -2% | -$139K | ﹤0.01% | 3454 |
|
|
2024
Q4 | $9.97M | Buy |
5,011,857
+612,723
| +14% | +$1.22M | ﹤0.01% | 3386 |
|
|
2024
Q3 | $13.9M | Buy |
4,399,134
+844,392
| +24% | +$2.66M | ﹤0.01% | 3196 |
|
|
2024
Q2 | $11.2M | Buy |
+3,554,742
| New | +$11.2M | ﹤0.01% | 3278 |
|
|
2023
Q4 | – | Sell |
-529,890
| Closed | -$475K | – | 5301 |
|
|
2023
Q3 | $475K | Buy |
529,890
+61,385
| +13% | +$55.1K | ﹤0.01% | 4370 |
|
|
2023
Q2 | $1.01M | Sell |
468,505
-167,042
| -26% | -$359K | ﹤0.01% | 4210 |
|
|
2023
Q1 | $1.24M | Buy |
635,547
+108,756
| +21% | +$212K | ﹤0.01% | 4179 |
|
|
2022
Q4 | $2.02M | Buy |
526,791
+98,925
| +23% | +$380K | ﹤0.01% | 4050 |
|
|
2022
Q3 | $2.06M | Sell |
427,866
-38,938
| -8% | -$188K | ﹤0.01% | 4099 |
|
|
2022
Q2 | $3.71M | Buy |
466,804
+162,575
| +53% | +$1.29M | ﹤0.01% | 3875 |
|
|
2022
Q1 | $4.47M | Buy |
304,229
+10,372
| +4% | +$152K | ﹤0.01% | 3950 |
|
|
2021
Q4 | $5.94M | Sell |
293,857
-19,784
| -6% | -$400K | ﹤0.01% | 3859 |
|
|
2021
Q3 | $8.52M | Buy |
313,641
+12,903
| +4% | +$350K | ﹤0.01% | 3686 |
|
|
2021
Q2 | $7.32M | Buy |
+300,738
| New | +$7.32M | ﹤0.01% | 3698 |
|
|
2021
Q1 | – | Sell |
-165,021
| Closed | -$5.28M | – | 5203 |
|
|
2020
Q4 | $5.28M | Hold |
165,021
| – | – | ﹤0.01% | 3615 |
|
|
2020
Q3 | $5.44M | Buy |
165,021
+521
| +0.3% | +$17.2K | ﹤0.01% | 3446 |
|
|
2020
Q2 | $7.7M | Buy |
+164,500
| New | +$7.7M | ﹤0.01% | 3269 |
|